Thanh bên bài viết
Số lượt xem PDF: 105
EVALUATION OF MEMBRANE AND SOLUBLE PD-L1 EXPRESSION IN ADVANCED-STAGE NON-SMALL CELL LUNG CANCER PATIENTS
Nội dung chính của bài viết
Tóm tắt
Objectives: To evaluate membrane and soluble PD-L1 expression in advanced-stage non-small cell lung cancer (NSCLC) patients. Subjects and methods: A prospective, cross-sectional study on 50 advanced-stage NSCLC patients treated at the Respiratory Center, Military Hospital 103 from January to September 2019; the control group consists of 30 normal people who had personal periodic health examination at the Outpatient Department, Military Hospital 103. Membrane PD-L1 (mPD-L1) expression assay was carried out applying immunohistochemistry on cancer tissue samples, using PD-L1 73 - 10 antibody. The serum level of soluble PD-L1 (sPD-L1) was measured using the ELISA technique. Results: 62% of lung cancer tissue samples were positive for mPD-L1 (TPS ³ 1%), of which 51.6% were highly positive and 48.4% low positive. The concentration of sPD-L1 in NSCLC group was significantly higher than that of the control group (2.11 ± 1.48 and 0.73 ± 0.57 ng/mL; p < 0.001). sPD-L1 concentration in the mPD-L1 negative group (1.61 ± 1.37 ng/mL) was statistically significantly lower than that in the mPD-L1 positive group (2.42 ± 1.49 ng/mL) (p = 0.03). At the cut-off value of 1.815 ng/mL, sPD-L1 had a diagnostic value for mPD-L1 positive with a sensitivity of 65% and specificity of 68%, area under the curve was 0.678 (95% CI: 0.521 - 0.835; p = 0.036). Conclusion: The rate of mPD-L1 positive expression in NSCLC tissue was 62%. The concentration of sPD-L1 in NSCLC patients was significantly higher than that in the control group. No significant relationship was found between the two forms of PD-L1 expression.
Chi tiết bài viết
Từ khóa
Ung thư phổi không tế bào nhỏ, membrane-bound programmed death ligand – 1 (mPD-L1), soluble programmed death ligand – 1 (sPD-L1)
Tài liệu tham khảo
2. Wu P., Wu D., et al. (2015). PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One; 10(6): e0131403.
3. Borghaei H., Paz-Ares L., et al. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med; 373(17): 1627-1639.
4. Brahmer J., Reckamp K.L., et al. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer; N Engl J Med; 373(2): 123-135.
5. Gettinger S., Rizvi N.A., et al. (2016). Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol; 34(25): 2980-2987.
6. Zhang J., Gao J., et al. (2015). Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer; 6(4): 534-538.
7. Chen Y., Wang Q., et al. (2011). Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine; 56(2): 231-238.
8. Cheng S., Zheng J., et al. (2015). PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer; Int J Biol Markers. 30(4): e364-368.
9. Murakami S., Shibaki R., et al. (2020). Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thorac Cancer; 11(12): 3585-3595.
10. Costantini A., Julie C., et al. (2018). Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab; Oncoimmunology; 7(8): e1452581.